MET and non-small cell lung carcinoma: ,61,62 Acquired MET kinase domain mutations identified in two patients at the end of treatment are known type 1 MET-inhibitor-resistance mechanisms63 and are reported here for the first time as resistance mechanisms in MET amplification NSCLC with MET TKI treatment.